Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNASDAQ:FWBINASDAQ:GBIONASDAQ:GRCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.95+5.4%$1.86$1.11▼$17.88$57.48M1.62739,685 shs295,622 shsFWBIFirst Wave BioPharma$3.28$2.33▼$60.00$7.34M1.28212,944 shs56,500 shsGBIOGeneration Bio$0.38-1.8%$0.39$0.32▼$3.65$25.67M2.66332,011 shs361,774 shsGRCEGrace Therapeutics$2.92+2.5%$2.62$1.75▼$4.97$29.61M0.8956,432 shs41,239 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+5.17%-3.12%+72.51%+71.01%-51.48%FWBIFirst Wave BioPharma0.00%0.00%0.00%0.00%0.00%GBIOGeneration Bio-2.05%+4.76%-2.47%-20.21%-88.39%GRCEGrace Therapeutics+2.46%-1.35%+12.31%+33.94%+291,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio2.1302 of 5 stars3.51.00.00.02.61.70.6FWBIFirst Wave BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AGBIOGeneration Bio4.1007 of 5 stars3.55.00.00.03.63.31.3GRCEGrace Therapeutics2.5956 of 5 stars3.50.00.00.03.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$30.25925.42% UpsideFWBIFirst Wave BioPharma 0.00N/AN/AN/AGBIOGeneration Bio 3.00Buy$7.331,814.71% UpsideGRCEGrace Therapeutics 3.00Buy$12.00310.96% UpsideCurrent Analyst Ratings BreakdownLatest FWBI, GRCE, ANVS, and GBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/17/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/14/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/14/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AFWBIFirst Wave BioPharmaN/AN/AN/AN/A$6.54 per shareN/AGBIOGeneration Bio$24.56M1.05N/AN/A$3.07 per share0.12GRCEGrace TherapeuticsN/AN/AN/AN/A$5.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$2.16N/AN/AN/AN/AN/A-311.00%8/13/2025 (Estimated)FWBIFirst Wave BioPharma-$15.80MN/A0.00N/AN/AN/A-102.83%-22.74%N/AGBIOGeneration Bio-$126.61M-$1.08N/AN/AN/A-782.86%-104.85%-49.54%8/6/2025 (Estimated)GRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%6/20/2025 (Estimated)Latest FWBI, GRCE, ANVS, and GBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23N/AN/AN/AN/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 million3/21/2025Q4 2024ANVSAnnovis Bio-$0.38-$0.43-$0.05-$0.43N/AN/A3/19/2025Q4 2024GBIOGeneration Bio-$0.31-$0.32-$0.01-$0.32$2.92 million$4.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AFWBIFirst Wave BioPharmaN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.662.66FWBIFirst Wave BioPharma0.401.211.58GBIOGeneration BioN/A6.346.34GRCEGrace TherapeuticsN/A6.066.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%FWBIFirst Wave BioPharma12.30%GBIOGeneration Bio95.22%GRCEGrace Therapeutics6.08%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%FWBIFirst Wave BioPharma0.49%GBIOGeneration Bio21.80%GRCEGrace Therapeutics13.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million9.64 millionOptionableFWBIFirst Wave BioPharma92.48 million2.46 millionNot OptionableGBIOGeneration Bio15067.04 million52.70 millionOptionableGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/AFWBI, GRCE, ANVS, and GBIO HeadlinesRecent News About These CompaniesGRCE: Progress ReportJune 5, 2025 | msn.comGRCE Grace Therapeutics, Inc.June 1, 2025 | seekingalpha.comThis Grace Therapeutics Insider Increased Their Holding By 12% Last YearMay 25, 2025 | finance.yahoo.comBiotech Stock Ends Week On High Note Following Bullish Coverage InitiationMay 2, 2025 | msn.comGrace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104April 9, 2025 | globenewswire.comGrace Therapeutics files to sell 8.84M shares of common stock for holdersMarch 10, 2025 | markets.businessinsider.comGrace Therapeutics Files Form S-3 for Flexible Securities OfferingMarch 10, 2025 | tipranks.comNew Biotech Stocks at Investorideas.comFebruary 28, 2025 | investorideas.comGrace Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comGRCE: STRIVE-ON Results ReportedFebruary 21, 2025 | finance.yahoo.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | markets.businessinsider.comGrace Therapeutics reports Q3 EPS (36c), consensus (46c)February 13, 2025 | markets.businessinsider.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | globenewswire.comGrace Therapeutics secures $15m for GTx-104 pre-commercial developmentFebruary 11, 2025 | finance.yahoo.comGrace Therapeutics price target raised to $11 from $8 at Craig-HallumFebruary 11, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for Grace Therapeutics (GRCE)February 11, 2025 | markets.businessinsider.comGrace Therapeutics, Inc.: Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAHFebruary 10, 2025 | finanznachrichten.deGrace Therapeutics reports positive Phase 3 trial results for GTx-104February 10, 2025 | msn.comGrace Therapeutics secures up to $30 million financingFebruary 10, 2025 | msn.comGrace Therapeutics announces private placement financing of up to $30MFebruary 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFWBI, GRCE, ANVS, and GBIO Company DescriptionsAnnovis Bio NYSE:ANVS$2.95 +0.15 (+5.36%) As of 06/12/2025 03:58 PM EasternAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.First Wave BioPharma NASDAQ:FWBIFirst Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.Generation Bio NASDAQ:GBIO$0.38 -0.01 (-1.79%) As of 06/12/2025 04:00 PM EasternGeneration Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Grace Therapeutics NASDAQ:GRCE$2.92 +0.07 (+2.46%) As of 06/12/2025 03:17 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
